Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare

599 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ASND Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Ascendis

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$241.85

▲(36.48%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $241.85 with a high forecast of $400.00 and a low forecast of $194.00. The average price target represents a 36.48% change from the last price of $177.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","401":"$401","193.25":"$193.3","262.5":"$262.5","331.75":"$331.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$400.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":241.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$241.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":194,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$194.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,193.25,262.5,331.75,401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,172,189.53846153846155,207.0769230769231,224.6153846153846,242.15384615384616,259.69230769230774,277.2307692307692,294.7692307692308,312.3076923076923,329.84615384615387,347.3846153846154,364.9230769230769,382.46153846153845,{"y":400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,172,177.37307692307692,182.74615384615385,188.11923076923077,193.4923076923077,198.8653846153846,204.23846153846154,209.61153846153846,214.98461538461538,220.3576923076923,225.73076923076923,231.10384615384615,236.47692307692307,{"y":241.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,172,173.69230769230768,175.3846153846154,177.07692307692307,178.76923076923077,180.46153846153845,182.15384615384616,183.84615384615384,185.53846153846155,187.23076923076923,188.92307692307693,190.6153846153846,192.30769230769232,{"y":194,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":133.98,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$400.00

Average Price Target$241.85

Lowest Price Target$194.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

07/15/25

Ascendis Pharma's Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating

David LebowitzCiti

Citi

$213→$243

Buy

37.13%

Upside

Reiterated

07/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Biogen (NASDAQ: BIIB)

Tazeen AhmadBank of America Securities

Bank of America Securities

―

Buy

―

Reiterated

07/14/25

Ascendis Pharma (ASND) Gets a Buy from Bank of America Securities

Yun ZhongWedbush

Wedbush

$212

Buy

19.64%

Upside

Reiterated

07/14/25

Ascendis Pharma's Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating

Eliana MerleUBS

UBS

$197→$306

Buy

72.69%

Upside

Reiterated

07/09/25

Ascendis Pharma (ASND) Gets a Buy from UBS

Derek ArchilaWells Fargo

Wells Fargo

$100→$400

Buy

125.73%

Upside

Reiterated

07/08/25

Positive Outlook for Ascendis Pharma Driven by Yorvipath's Growing Adoption and Revenue Potential

Luca IssiRBC Capital

RBC Capital

$210

Buy

18.51%

Upside

Reiterated

07/07/25

RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Maxwell SkorMorgan Stanley

Morgan Stanley

$250

Buy

41.08%

Upside

Initiated

07/02/25

Analysts Conflicted on These Healthcare Names: Milestone Pharmaceuticals (NASDAQ: MIST), Exact Sciences (NASDAQ: EXAS) and Ascendis Pharma (NASDAQ: ASND)

Leland GershellOppenheimer

Oppenheimer

$215→$224

Buy

26.41%

Upside

Reiterated

06/13/25

Ascendis Pharma price target raised to $224 from $215 at OppenheimerAscendis Pharma price target raised to $224 from $215 at Oppenheimer

Joseph SchwartzLeerink Partners

Leerink Partners

$200

Buy

12.87%

Upside

Reiterated

06/10/25

Analysts Conflicted on These Healthcare Names: Ascendis Pharma (NASDAQ: ASND), Amgen (NASDAQ: AMGN) and Elevation Oncology (NASDAQ: ELEV)

Yaron WerberTD Cowen

TD Cowen

$194

Buy

9.48%

Upside

Reiterated

06/10/25

TD Cowen Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Kelly ShiJefferies

Jefferies

$233

Buy

31.49%

Upside

Reiterated

06/09/25

Ascendis Pharma's TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$212

Buy

19.64%

Upside

Reiterated

05/27/25

Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus

Li WatsekCantor Fitzgerald

Cantor Fitzgerald

$280→$200

Buy

12.87%

Upside

Reiterated

05/12/25

Cantor Fitzgerald Remains a Buy on Ascendis Pharma (ASND)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$260

Buy

46.73%

Upside

Reiterated

04/25/25

Ascendis Pharma (ASND) Gets a Buy from Evercore ISI

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

07/15/25

Ascendis Pharma's Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating

David LebowitzCiti

Citi

$213→$243

Buy

37.13%

Upside

Reiterated

07/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Biogen (NASDAQ: BIIB)

Tazeen AhmadBank of America Securities

Bank of America Securities

―

Buy

―

Reiterated

07/14/25

Ascendis Pharma (ASND) Gets a Buy from Bank of America Securities

Yun ZhongWedbush

Wedbush

$212

Buy

19.64%

Upside

Reiterated

07/14/25

Ascendis Pharma's Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating

Eliana MerleUBS

UBS

$197→$306

Buy

72.69%

Upside

Reiterated

07/09/25

Ascendis Pharma (ASND) Gets a Buy from UBS

Derek ArchilaWells Fargo

Wells Fargo

$100→$400

Buy

125.73%

Upside

Reiterated

07/08/25

Positive Outlook for Ascendis Pharma Driven by Yorvipath's Growing Adoption and Revenue Potential

Luca IssiRBC Capital

RBC Capital

$210

Buy

18.51%

Upside

Reiterated

07/07/25

RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Maxwell SkorMorgan Stanley

Morgan Stanley

$250

Buy

41.08%

Upside

Initiated

07/02/25

Analysts Conflicted on These Healthcare Names: Milestone Pharmaceuticals (NASDAQ: MIST), Exact Sciences (NASDAQ: EXAS) and Ascendis Pharma (NASDAQ: ASND)

Leland GershellOppenheimer

Oppenheimer

$215→$224

Buy

26.41%

Upside

Reiterated

06/13/25

Ascendis Pharma price target raised to $224 from $215 at OppenheimerAscendis Pharma price target raised to $224 from $215 at Oppenheimer

Joseph SchwartzLeerink Partners

Leerink Partners

$200

Buy

12.87%

Upside

Reiterated

06/10/25

Analysts Conflicted on These Healthcare Names: Ascendis Pharma (NASDAQ: ASND), Amgen (NASDAQ: AMGN) and Elevation Oncology (NASDAQ: ELEV)

Yaron WerberTD Cowen

TD Cowen

$194

Buy

9.48%

Upside

Reiterated

06/10/25

TD Cowen Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Kelly ShiJefferies

Jefferies

$233

Buy

31.49%

Upside

Reiterated

06/09/25

Ascendis Pharma's TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$212

Buy

19.64%

Upside

Reiterated

05/27/25

Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus

Li WatsekCantor Fitzgerald

Cantor Fitzgerald

$280→$200

Buy

12.87%

Upside

Reiterated

05/12/25

Cantor Fitzgerald Remains a Buy on Ascendis Pharma (ASND)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$260

Buy

46.73%

Upside

Reiterated

04/25/25

Ascendis Pharma (ASND) Gets a Buy from Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+6.66%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +6.66% per trade.

3 Months

xxx

Success Rate

20/26 ratings generated profit

Average Return

+11.49%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +11.49% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

25/29 ratings generated profit

Average Return

+22.50%

reiterated a buy rating 5 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 86.21% of your transactions generating a profit, with an average return of +22.50% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+51.92%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +51.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ASND has received 41 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 241.85.

Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is -$1.48 with a range of -$2.22 to -$0.92. The previous quarter’s EPS was -$1.84. ASND beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year ASND has Preformed in-line its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $165.69M with a range of $129.83M to $197.70M. The previous quarter’s sales results were $106.25M. ASND beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year ASND has Preformed in-line its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 241.85.

What is ASND’s upside potential, based on the analysts’ average price target?

Ascendis Pharma has 36.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ASND a Buy, Sell or Hold?

Ascendis Pharma has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ascendis Pharma’s price target?

The average price target for Ascendis Pharma is 241.85. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $400.00 ,the lowest forecast is $194.00. The average price target represents 36.48% Increase from the current price of $177.2.

What do analysts say about Ascendis Pharma?

Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ASND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ascendis Pharma (ASND) Stock Forecast & Price Target

ASND Analyst Ratings

ASND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ascendis Pharma

ASND Analyst Recommendation Trends

ASND Financial Forecast

ASND Earnings Forecast

ASND Sales Forecast

ASND Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts